Xgenomes Corp.
Cambridge, MA
- UEI
- URQZNV343D65
- CAGE
- 9VBZ3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 750 Main St, Cambridge, MA 02139, USA
- Website
- xgenomes.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $449,860 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | National Aeronautics and Space Administration | $449,860 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase i gravity-independent single-molecule multi-omic sequencing | Shared Services Center | $224,937 | |
| Sttr phase i gravity-independent single-molecule multi-omic sequencing | Shared Services Center | $224,923 |
Grant awards
Similar vendors
About the company
Xgenomes Corp., a minority-owned, Subcontinent Asian American-owned biotechnology firm based in Cambridge, Massachusetts, develops advanced genomic sequencing and molecular analysis platforms for federal R&D customers as a prime recipient of federal grants and contracts under total small business set-asides. The vendor operates exclusively as a prime across its current federal footprint (100% of awards), with no subcontract work, and competes under small business set-asides across all recent awards.
Xgenomes' capability portfolio centers on single-molecule imaging and sequencing technology, machine learning algorithms for molecular diagnostics, and circulating tumor DNA (ctDNA) analysis platforms. Recent federal work includes two Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I contracts awarded by NASA's Shared Services Center on September 30, 2026, each valued at approximately $224,900 and addressing gravity-independent single-molecule multi-omic sequencing. These definitive contracts run through March and October 2027, respectively. In parallel, Xgenomes holds four federal research grants as prime recipient under the Biomedical Research and Research Training program (CFDA 93.859), advancing machine learning architectures for single-molecule localization microscopy (SMLM) video analysis ($349,280 from the National Institute of General Medical Sciences, September 2025 through September 2027); novel ctDNA analysis platforms for liquid biopsy assays ($349,280 implied, National Cancer Institute, September 2025 through August 2027); epigenetic modification sequencing by oligonucleotide binding kinetics (National Human Genome Research Institute, June 2025 through February 2027); and super-resolution single-molecule sequencing technology ($384,418, National Human Genome Research Institute, September 2024 through May 2025).
Customer concentration splits between NASA's Shared Services Center, which anchors the two recent SBIR/STTR contracts ($450,000 combined potential value), and the National Institutes of Health at three component institutes (National Human Genome Research Institute, National Cancer Institute, National Institute of General Medical Sciences), which together account for four grant awards. All four agencies listed (100% coverage) are active. Activity has accelerated from one award in 2024 to three in 2025 and two in 2026 (nine weeks old through October 2026). Five awards with combined potential value of $450,000 reach ultimate completion within the next twenty-four months, triggering recompete exposure in that window. Notably, combined dollars obligated across all awards ($2.4 million) exceed combined potential value ($450,000) by a factor of 5.29, indicating substantial contract modifications or invoiced revenue against Phase I and Phase II awards as development progresses.
Quick answers
Is Xgenomes Corp. registered in SAM.gov?
Yes. Xgenomes Corp.'s SAM.gov registration is active through August 22, 2027.
How much has Xgenomes Corp. received in federal contracts?
Federal contracts obligated $449,860 to Xgenomes Corp. in fiscal years 2023 through 2027.
What is Xgenomes Corp.'s most recent federal award?
Xgenomes Corp.'s most recent federal contract award is Sbir phase i gravity-independent single-molecule multi-omic sequencing (80NSSC26C0372), from Shared Services Center, on September 30, 2026.
On GovTribe
See Xgenomes Corp.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors